Celularity Inc (CELU) - News Archive

On December 10, 2024, Celularity Inc. a company specializing in regenerative and cellular medicine, announced a pivotal development that has sent ripples through the investment community: it has restored its compliance...

Celularity Inc. Faces Nasdaq Compliance Challenges Amidst Corporate Updates and Appeals FLORHAM PARK, N.J. November 27, 2024 Celularity Inc. (Nasdaq: CELU), a pioneering regenerative medicine company focused on developi...

A New Era in Regenerative Medicine: Groundbreaking for Fontaine Vitale in BaliIn a significant advancement for the field of regenerative medicine, Celularity Inc. (Nasdaq: CELU) has unveiled a transformative partnership...

Celularity Inc. s Corporate Update: Navigating Financial Compliance and Future ProspectsIn an important corporate announcement, Celularity Inc. (Nasdaq: CELU), a Florham Park, N.J.-based leader in regenerative and cellu...

Celularity Inc. s Journey from Promise to Peril: Navigating Nasdaq Compliance ChallengesThe calendar year 2024 has been tumultuous for Florham Park-based Celularity Inc. (Nasdaq: CELU), a regenerative medicine entity re...

Celularity s Bold Step into Advanced Biomaterials: What You Need to nKowOn October 16, 2024, Celularity Inc. (Nasdaq: CELU), a leading name in regenerative and cellular medicine, announced a significant enhancement to i...

In a recent press release, Celularity Inc. (Nasdaq: CELU), a regenerative medicine company focused on developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced its receipt of a...

CSIMarket.com aims to provide evidence-based research and analysis on the latest advancements in the pharmaceutical industry. In this article, we analyze two key articles to highlight the benefits of placental circulati...

Tendon injuries are a significant cause of morbidity and reduced quality of life, affecting millions of people worldwide. Current treatment options often fall short in achieving optimal functional recovery, highlighting...

Celularity, a leading global biotechnology company specializing in advanced biomaterial products, has recently announced impressive net sales performance for the first quarter of 2024. The company has not only exceeded...

IntroductionCelularity, a leading cell therapeutics company, has achieved a significant milestone with the receipt of Healthcare Common Procedure Coding System (HCPCS) Q Code approval from the U.S. Centers for Medicare...

Celularity Seeks Orphan Drug Designation for PDA-002 in Facioscapulohumeral Muscular Dystrophy TreatmentCelularity, a leading biotechnology company focused on the development of innovative cellular therapies, has recent...

Celularity, a leading clinical-stage cell therapeutics company, is set to present groundbreaking data at the AACR Annual Meeting in 2024. The data showcases the potential of PT-CD16, a genetically modified allogeneic ce...

Celularity, a biotechnology company specializing in allogeneic cell therapies and advanced biomaterial products, recently announced a significant development that is set to impact its stock value. The company s Board of...

In line with an impressive growth trajectory initiated in 2023, Celularity Inc. recently unveiled its net sales projections for the first quarter and the entire year of 2024. Notably, the company is expecting a triple-d...

Celularity Inc. recently posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder, outlining the company s progress and future plans. This article will delve into the highlights fro...

Celularity, a leading biotechnology company specializing in allogeneic cell therapies and advanced biomaterial products, has recently entered into an exclusive strategic commercialization agreement with BioCellgraft. Th...